Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy
Open Access
- 1 February 2011
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 19 (2), 335-344
- https://doi.org/10.1038/mt.2010.264
Abstract
No abstract availableKeywords
This publication has 87 references indexed in Scilit:
- Enhancing the Therapeutic Effect Against Ovarian Cancer Through a Combination of Viral Oncolysis and Antigen-specific ImmunotherapyMolecular Therapy, 2010
- Differences in Brain Volume, Hippocampal Volume, Cerebrovascular Risk Factors, and Apolipoprotein E4 Among Mild Cognitive Impairment SubtypesArchives of Neurology, 2009
- Vesicular Stomatitis Virus as a Novel Cancer Vaccine Vector to Prime Antitumor Immunity Amenable to Rapid Boosting With AdenovirusMolecular Therapy, 2009
- Everyday functioning in mild cognitive impairment and its relationship with executive cognitionInternational Journal of Geriatric Psychiatry, 2009
- Longitudinal Changes in Memory and Executive Functioning are Associated with longitudinal change in instrumental activities of daily living in older AdultsThe Clinical Neuropsychologist, 2009
- A Herpes Oncolytic Virus Can Be Delivered Via the Vasculature to Produce Biologic Changes in Human Colorectal CancerMolecular Therapy, 2009
- Recombinant Newcastle Disease Virus as a Vaccine Vector for Cancer TherapyMolecular Therapy, 2008
- Efficacy and Safety of the Oncolytic Herpes Simplex Virus rRp450 Alone and Combined With CyclophosphamideMolecular Therapy, 2008
- Frequency and course of mild cognitive impairment in a multiethnic communityAnnals of Neurology, 2008
- Cognitive and neuroimaging predictors of instrumental activities of daily livingJournal of the International Neuropsychological Society, 2007